BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors

This clinical trial is testing a new drug, BI-1910, for people with advanced solid tumors. These are cancers that have spread and didn't respond to regular treatments. BI-1910 is being tested alone and with another drug called pembrolizumab, often used in cancer treatment. The trial aims to find out how safe the drug is, how much of it can be given safely, and the best dose for future studies.

Participants will get the treatment every three weeks. There are two parts to this trial, where the first part finds the right dose and the second part tests this dose on more people.

• This study involves regular visits for treatment every 3 weeks.
• Participants should have tried standard cancer treatments without success.
• There are some risks, like side effects, and participants must meet specific health criteria to join.

Before joining, participants must be 18 or older, have a life expectancy of at least 12 weeks, and meet other health requirements. They should not have certain conditions, like active brain cancer, or be on certain medications. Women who can get pregnant must use birth control. This study is not suitable for everyone, so discuss with your doctor to see if it’s right for you.